



Cognition and Memory Enhancement Drugs: *Technologies and Global Markets*

July 2018

Sangeeta Rai

Report Code: PHM184A

Table of Contents

- Chapter 1: Introduction 1
 - Study Goals and Objectives..... 1
 - Reasons for Doing This Study..... 1
 - Scope of Report..... 1
 - Information Sources and Methodology 2
 - Intended Audience..... 2
 - Geographic Breakdown..... 3
 - Analyst’s Credentials..... 5
 - Related BCC Research Reports..... 5
- Chapter 2: Summary and Highlights..... 7
- Chapter 3: Market and Technology Background 11
 - Market Definition..... 11
 - Ethics and Cognition and Memory-enhancing Drugs 11
 - Treatments Available for Dementia..... 12
 - Cholinesterase Inhibitors 12
 - Memantine..... 13
 - Nondrug Treatments for Dementia..... 13
 - Availability of Dementia Treatments 14
 - Treatment for Other Symptoms of Dementia Including Aggression and Anxiety 14
 - Side Effects of Cognition and Memory-enhancing Drugs 16
 - Benefits and Side Effects of Consuming Cognition Drugs..... 17
 - Guidance Given by the American Academy of Neurology..... 19
 - Current Cognition Enhancers 19
 - Physical Exercise..... 20
 - Diet and Nutrition 20
 - Social Engagement 21
 - Sleep 21
 - Computer Training Programs 22
 - ADHD Drugs, Symptoms, and Side Effects 22
 - Use of Pharmacological Cognitive Enhancers by Healthy Individuals 29
 - Enhancement of Executive Functions 30
 - Use of Cannabis in Adolescence..... 31
 - Use of Illicit and Prescription Drugs for Cognitive or Mood Enhancement Among Surgeons 34
 - Study Reported in *BMC Medicine* in 2013 and Other Studies..... 34
 - Executive Functions..... 39
 - Working Memory 39
 - Neuropsychiatric Disorders..... 39
 - Enhancer Drug Use Trends Among Youth..... 44
 - Future Prediction of Social Acceptance of Cognition and Memory-enhancing Drugs..... 45
 - Patent Litigation Claims in the Cognition and Memory-enhancing Drugs Market..... 46
 - Different Patent Infringement Types 46
 - Clinical Guidelines 47
 - Clinical Guidelines for Cognitive and Behavioral Problems in Dementia 47
 - Clinical Practice Guidelines for Dementia in Australia 48
 - Technology Trends..... 49
 - Recent Studies Highlighting Potential of Cognition Drugs in Chess 50

| | |
|-----------------------|----|
| Market Dynamics | 52 |
| Drivers | 52 |
| Restraints..... | 54 |
| Opportunities | 55 |

Chapter 4: Global Cognition and Memory-enhancing Drugs Market Breakdown by Product Type 57

| | |
|--|----|
| ADHD, Attention Deficit Hyperactivity Disorder; MPH, Methylphenidate | 58 |
| Prohibition of Cognition Enhancers in Healthy Individuals | 58 |
| Global Cognition and Memory-enhancing Drugs Market..... | 60 |
| Aricept | 61 |
| Exelon | 62 |
| Reminyl..... | 64 |
| Namenda | 65 |
| Adderall | 66 |
| Ritalin..... | 67 |
| Dexedrin | 68 |
| Other Cognition and Memory-Enhancing Products..... | 69 |

Chapter 5: Global Cognition and Memory-enhancing Drugs Market Breakdown by Application..... 72

| | |
|--|----|
| Alzheimer’s Disease | 74 |
| Brain Changes Associated with Alzheimer’s Disease | 75 |
| Mild Cognitive Impairment (MCI) – A Potential Precursor to Alzheimer’s and Other Dementias..... | 77 |
| Recent Case Study on Alzheimer’s Disease Drug: 2017 | 78 |
| Case Study on Alzheimer’s Disease Drug: 2015 | 79 |
| Mortality and Morbidity Because of Alzheimer’s Disease | 79 |
| Healthcare Expenditure on Alzheimer’s Disease | 82 |
| Emergence of Biomarkers as Diagnostic Tool for Alzheimer’s Disease | 83 |
| Alzheimer’s Disease Facts | 83 |
| Difference between Alzheimer’s Disease and Dementia | 84 |
| Susceptibility Factors for Alzheimer’s Disease | 84 |
| Causes of Alzheimer’s Disease | 87 |
| Diagnosis of Alzheimer’s Disease | 87 |
| Screening of Other Health Conditions of People Suffering from Alzheimer’s Disease | 87 |
| Importance of Comprehensive Clinical Evaluation in the Case of Alzheimer’s Disease Patients | 88 |
| Education Sector | 88 |
| Sports | 90 |
| Other Applications | 91 |
| Cognitive Impairment in People Suffering from Parkinson’s Disease..... | 91 |
| Treatment of Parkinson’s Disease Dementia | 93 |
| Cognitive Decline in Patients Suffering from Parkinson’s Disease Causing Further Complexities..... | 95 |

Chapter 6: Global Cognition and Memory-enhancing Drugs Market Breakdown by Region..... 100

| | |
|--------------------|-----|
| North America..... | 101 |
| U.S. | 103 |
| Canada..... | 103 |
| Mexico | 104 |
| Europe..... | 105 |
| U.K. | 107 |

| | |
|--|------------|
| Germany..... | 108 |
| France..... | 109 |
| Rest of Europe..... | 110 |
| Asia-Pacific..... | 110 |
| China..... | 112 |
| Japan..... | 113 |
| Australia..... | 114 |
| India..... | 115 |
| Rest of Asia..... | 116 |
| ROW..... | 116 |
| Brazil..... | 118 |
| Turkey..... | 119 |
| South Africa..... | 119 |
| Chapter 7: Patent Review..... | 121 |
| Patent Analysis..... | 121 |
| Patents Filed in Asia-Pacific..... | 122 |
| Patents Filed in North America..... | 123 |
| Chapter 8: Analysis of Market Opportunities..... | 125 |
| Product Approval..... | 126 |
| Business Collaboration..... | 127 |
| Chapter 9: Company Profiles..... | 129 |
| Appendix: Patents, Drugs and Cognitive Enhancers..... | 143 |
| List of Patents North America..... | 143 |
| List of Patents Applied Globally..... | 144 |
| List of Drugs and Cognitive Enhancers..... | 144 |
| 1,3-Dimethylamylamine..... | 144 |
| 5-HTP..... | 144 |
| Acetyl L-Carnitine..... | 144 |
| Adrafinil..... | 145 |
| Agmatine..... | 145 |
| Alpha-GPC..... | 145 |
| Alpha-Lipoic Acid..... | 145 |
| Aniracetam..... | 146 |
| Bacopa Monnieri..... | 146 |
| Blueberry..... | 146 |
| Boswellia Serrata..... | 146 |
| Caffeine..... | 146 |
| CDP-Choline..... | 147 |
| Celastrus Paniculatus..... | 147 |
| Clitoria Ternatea (Shanka Pushpi)..... | 147 |
| Cocoa Flavanols..... | 147 |
| Coluracetam..... | 147 |
| Convolvulus Pluricaulis (Shankhapushpi)..... | 148 |
| Creatine..... | 148 |
| D-Serine..... | 148 |
| Dehydroepiandrosterone..... | 148 |
| Dimocarpus Longan..... | 148 |
| Emblica Officinalis (Amla)..... | 148 |

| | |
|---------------------------------------|-----|
| Fish Oil (DHA, EPA, Omega-3)..... | 149 |
| GABA..... | 149 |
| Ginkgo biloba..... | 149 |
| Glycine..... | 149 |
| Gotu Kola (Centella Asiatica)..... | 149 |
| Grape Seed Extract..... | 150 |
| Green Tea Catechins..... | 150 |
| Hordenine..... | 150 |
| Huperzine-A..... | 150 |
| Idebenone..... | 150 |
| Kava..... | 151 |
| Krill Oil..... | 151 |
| L-DOPA..... | 151 |
| L-Tyrosine..... | 151 |
| Magnolia Officinalis..... | 151 |
| Melissa Officinalis (Lemon Balm)..... | 152 |
| Modafinil..... | 152 |
| Morus Alba..... | 152 |
| Mucuna Pruriens..... | 152 |
| Muira Puama..... | 152 |
| Nardostachys Jatamansi..... | 153 |
| Nefiracetam..... | 153 |
| Nicotine..... | 153 |
| Nigella Sativa..... | 153 |
| Noopept..... | 153 |
| Oxiracetam..... | 154 |
| Panax Ginseng..... | 154 |
| Phenylethylamine..... | 154 |
| Phenylpiracetam..... | 154 |
| Phosphatidylserine..... | 154 |
| Piracetam..... | 155 |
| Polygala Tenuifolia..... | 155 |
| Pramiracetam..... | 155 |
| PRL-8-53..... | 155 |
| Pueraria Lobata..... | 155 |
| Pycnogenol..... | 156 |
| Pyritinol..... | 156 |
| Resveratrol..... | 156 |
| Rhodiola Rosea..... | 156 |
| S-Adenosyl Methionine..... | 156 |
| Sarcosine..... | 157 |
| Scutellaria baicalensis..... | 157 |
| Sulbutiamine..... | 157 |
| Sunifiram..... | 157 |
| Theanine..... | 157 |
| Uridine..... | 158 |
| Vinpocetine..... | 158 |
| Vitamin B12..... | 158 |
| Yamabushitake..... | 158 |
| Yerba Mate..... | 158 |
| Zinc..... | 159 |

| | |
|---------------------------|-----|
| About BCC Research..... | 160 |
| About BCC Research..... | 161 |
| BCC Membership | 161 |
| BCC Custom Research | 161 |

List of Tables

| | |
|---|-----|
| Summary Table: Global Market for Cognition and Memory-enhancing Drugs, by Region, Through 2022 (\$ Millions) | 8 |
| Table 1 Key Trends in Global Cognition Drugs and Memory Enhancers..... | 49 |
| Table 2 Drugs Used to Enhance Cognitive Function | 57 |
| Table 3 Global Market for Cognition and Memory-enhancing Drugs, by Product, Through 2022 (\$ Millions) | 61 |
| Table 4 Global Market for Aricept, by Region, Through 2022 (\$ Millions) | 62 |
| Table 5 Global Market for Exelon, by Region, Through 2022 (\$ Millions) | 63 |
| Table 6 Administration of Exelon..... | 63 |
| Table 7 Global Market for Reminyl, by Region, Through 2022 (\$ Millions)..... | 64 |
| Table 8 Companies Manufacturing Reminyl..... | 65 |
| Table 9 Global Market for Namenda, by Region, Through 2022 (\$ Millions) | 66 |
| Table 10 Global Market for Adderall, by Region, Through 2022 (\$ Millions) | 67 |
| Table 11 Global Market for Ritalin, by Region, Through 2022 (\$ Millions) | 68 |
| Table 12 Global Market for Dexedrin, by Region, Through 2022 (\$ Millions) | 69 |
| Table 13 Global Market for Other Cognition and Memory-enhancing Drugs, by Region, Through 2022 (\$ Millions) | 70 |
| Table 14 Causes of Dementia and Associated Characteristics | 73 |
| Table 15 Global Market for Cognition and Memory-enhancing Drugs, by Application, Through 2022 (\$ Millions) | 74 |
| Table 16 Global Cognition and Memory-enhancing Drugs Market for Alzheimer’s Disease, by Region, Through 2022 (\$ Millions)..... | 75 |
| Table 17 Causes of Dementia and Associated Characteristics | 76 |
| Table 18 Global Cognition and Memory-enhancing Drugs Market in the Education Sector, by Region, Through 2022 (\$ Millions)..... | 89 |
| Table 19 Global Cognition and Memory-enhancing Drugs Market in Sports, by Region, Through 2022 (\$ Millions) | 90 |
| Table 20 Global Cognition and Memory-enhancing Drugs Market in Other Applications, by Region, Through 2022 (\$ Millions)..... | 91 |
| Table 21 Global Market for Cognition and Memory-enhancing Drugs, by Region, Through 2022 (\$ Millions) | 100 |
| Table 22 North American Market for Cognition and Memory-enhancing Drugs, by Country, Through 2022 (\$ Millions) | 101 |
| Table 23 North American Market for Cognition and Memory-enhancing Drugs, by Product, Through 2022 (\$ Millions) | 102 |
| Table 24 North American Market for Cognition and Memory-enhancing Drugs, by Application, Through 2022 (\$ Millions) | 102 |
| Table 25 European Market for Cognition and Memory-enhancing Drugs, by Country, Through 2022 (\$ Millions) | 106 |
| Table 26 European Market for Cognition and Memory-enhancing Drugs, by Product, Through 2022 (\$ Millions) | 106 |
| Table 27 European Market for Cognition and Memory-enhancing Drugs, by Application, Through 2022 (\$ Millions) | 107 |
| Table 28 Asia-Pacific Market for Cognition and Memory-enhancing Drugs, by Country, Through 2022 (\$ Millions) | 111 |
| Table 29 Asia-Pacific Market for Cognition and Memory-enhancing Drugs, by Product, Through 2022 (\$ Millions) | 111 |

| | |
|--|-----|
| Table 30 Asia-Pacific Market for Cognition and Memory-enhancing Drugs, by Application, Through 2022 (\$ Millions) | 112 |
| Table 31 Rest of the World Market for Cognition and Memory-enhancing Drugs, by Country, Through 2022 (\$ Millions) | 117 |
| Table 32 Rest of the World Market for Cognition and Memory-enhancing Drugs, by Product, Through 2022 (\$ Millions) | 117 |
| Table 33 Rest of the World Market for Cognition and Memory-enhancing Drugs, by Application, Through 2022 (\$ Millions) | 118 |
| Table 34 Patent Review of Cognition Drugs Market, 2013-2016 | 121 |
| Table 35 Patent Review of Cognition Drugs Market, by Region, 2013-2016..... | 122 |
| Table 36 Allergan’s Financials, 2014-2016 (\$ Millions)..... | 130 |
| Table 37 Allergan’s Developments, 2014-2017 | 130 |
| Table 38 Cognition Therapeutics’ Developments, 2014-2017..... | 133 |
| Table 39 Novartis’ Financials, 2014-2016 (\$ Millions) | 135 |
| Table 40 Novartis’ Developments, 2014-2017..... | 136 |
| Table 41 Pfizer’s Financials, 2014-2016 (\$ Millions)..... | 138 |
| Table 42 Pfizer’s Developments, 2014-2017 | 138 |
| Table 43 Shire’s Financials, 2014-2016 (\$ Millions)..... | 139 |
| Table 44 Teva’s Financials, 2014-2016 (\$ Millions) | 141 |
| Table 45 Teva’s Developments, 2014-2017 | 141 |
| Table 46 List of Patents, North America | 143 |
| Table 47 List of Patents Applied Globally | 144 |

List of Figures

| | |
|---|-----|
| Summary Figure: Global Market for Cognition and Memory-enhancing Drugs, by Region, 2016-2022 (\$ Millions) | 8 |
| Figure 1 Medication Overdose: Cognitive Impairment..... | 24 |
| Figure 2 Acetylcholinesterase Inhibitor Used in the Alzheimer’s Disease Management | 25 |
| Figure 3 Role of Modafinil in the Management of Alzheimer’s Disease..... | 26 |
| Figure 4 Off-license Use of Pharmacological Cognitive-Enhancing Drugs | 27 |
| Figure 5 Risk Associated with the Excessive Use of Cannabis | 32 |
| Figure 6 Role of Adolescence in the Cognition Process | 33 |
| Figure 7 Statistical Analysis of Aging Population in the U.S. (%)..... | 53 |
| Figure 8 Global Market Segmentation for Cognition and Memory-enhancing Drugs, by Type | 60 |
| Figure 9 Global Market for Cognition and Memory-enhancing Drugs, by Application | 72 |
| Figure 10 The Stages of Alzheimer’s Disease..... | 80 |
| Figure 11 The Stages of Parkinson’s Disease | 97 |
| Figure 12 U.S. Market for Cognition and Memory-enhancing Drugs, 2016-2022 (\$ Millions)..... | 103 |
| Figure 13 Canadian Market for Cognition and Memory-enhancing Drugs, 2016-2022 (\$ Millions) | 104 |
| Figure 14 Mexican Market for Cognition and Memory-enhancing Drugs, 2016-2022 (\$ Millions)..... | 105 |
| Figure 15 U.K. Market for Cognition and Memory-enhancing Drugs, 2016-2022 (\$ Millions)..... | 108 |
| Figure 16 German Market for Cognition and Memory-enhancing Drugs, 2016-2022 (\$ Millions) | 108 |
| Figure 17 French Market for Cognition and Memory-enhancing Drugs, 2016-2022 (\$ Millions) | 109 |
| Figure 18 Rest of Europe Market for Cognition and Memory-enhancing Drugs, 2016-2022 (\$ Millions)..... | 110 |
| Figure 19 Chinese Market for Cognition and Memory-enhancing Drugs, 2016-2022 (\$ Millions)..... | 113 |
| Figure 20 Japanese Market for Cognition and Memory-enhancing Drugs, 2016-2022 (\$ Millions)..... | 114 |
| Figure 21 Australian Market for Cognition and Memory-enhancing Drugs, 2016-2022 (\$ Millions) | 115 |
| Figure 22 Indian Market for Cognition and Memory-enhancing Drugs, 2016-2022 (\$ Millions) | 115 |
| Figure 23 Rest of Asia-Pacific Market for Cognition and Memory-enhancing Drugs, 2016-2022 (\$ Millions) | 116 |
| Figure 24 Brazilian Market for Cognition and Memory-enhancing Drugs, 2016-2022 (\$ Millions)..... | 118 |
| Figure 25 Turkey’s Market for Cognition and Memory-enhancing Drugs, 2016-2022 (\$ Millions)..... | 119 |
| Figure 26 South African Market for Cognition and Memory-enhancing Drugs, 2016-2022 (\$ Millions) .. | 119 |
| Figure 27 Strategies for Global Cognition and Memory-enhancing Drugs Market, 2014-2017 (%)..... | 125 |
| Figure 28 Market Players Adopting Several Strategies for Global Cognition and Memory-enhancing Drugs Market, 2014-2017 (%)..... | 126 |



About BCC Research

About BCC Research

With our unparalleled 45-year history, BCC Research provides comprehensive analyses of global market sizing, forecasting and industry intelligence, covering markets where advances in science and technology are improving the quality, standard and sustainability of businesses, economies and lives.

BCC Membership

From market sizing and forecasts, to opportunity assessments and competitive analyses, our expanding library gives you the data, insights and intelligence required to ensure your project is a success. Members benefit from ongoing, unlimited access to the category or collections of their choice, and most membership packages pay for themselves within two to three reports being accessed.

Did you buy this report? You may qualify to apply your purchase price toward a full membership. Call 866/285-7215 or e-mail info@bccresearch.com to request a demo.

BCC Custom Research

Our experts provide custom research projects to those working to identify new markets, introduce new products, validate existing market share, analyze competition and assess the potential for products to impact existing markets. With impressive academic credentials and broad and deep knowledge of global industrial markets, our independent analysts and consultants develop the facts, figures, analyses and assessments to inform the decisions that will move your company ahead. Confidential inquiries to: custom@bccresearch.com or 781/205-2429.

DISCLAIMER

The information developed in this report is intended to be as reliable as possible at the time of publication and is of a professional nature. This information does not constitute managerial, legal or accounting advice, nor should it be considered as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is speculative in nature. BCC Research and the author assume no responsibility for any loss or damage that might result from reliance on the reported information or from its use.

ISBN: 978-1-62296-789-6
July 2018